tirzepatide a1c LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes A new study shows that
Pay in 4 interest-free payments of $6.74 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
























